Abstract |
Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1.4 million patients diagnosed with cancer each year in the USA. This condition is characterized by progressive deterioration of a patient's nutritional status, weight loss, anorexia, diminished quality of life and increased mortality and morbidity. Current therapy with progestational, anti-inflammatory and anabolic agents is often ineffective and has a large number of undesirable effects. The newly developed nonsteroidal selective androgen receptor modulator Ostarine has demonstrated promising results in Phase I and II clinical trials, increasing total lean body mass, enhancing functional performance and decreasing total tissue percent fat. This selective androgen receptor modulator may have the ability to perform as a potent anabolic agent with minimal side effects on other organs (prostate and hair follicles), thus presenting a new strategy in managing cancer cachexia. However, more extensive data is required before its efficacy is confirmed.
|
Authors | Mihail F Zilbermint, Adrian S Dobs |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 5
Issue 8
Pg. 1211-20
(Oct 2009)
ISSN: 1744-8301 [Electronic] England |
PMID | 19852734
(Publication Type: Journal Article, Review)
|
Chemical References |
- Amides
- Anilides
- Receptors, Androgen
- ostarine
- propionamide
|
Topics |
- Amides
(pharmacology)
- Anilides
- Cachexia
(drug therapy, etiology)
- Clinical Trials as Topic
- Humans
- Neoplasms
(complications)
- Receptors, Androgen
(drug effects)
|